Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text
During the Biden administration, the HHS embraced an alternative test for "accepted medical use" that considers "widespread" clinical experience with a drug and requires "some credible scientific support" for at least one application.
Simplified Text
During the Biden administration, the Department of Health and Human Services (HHS) adopted an alternative test for "accepted medical use" that includes "widespread" clinical experience and "some credible scientific support."
Confidence Score
0.900
Claim Maker
The author
Context Type
News Article
Context Details
{
    "administration": "Biden administration"
}
Subject Tags
Regulation Drug Policy Biden Administration
UUID
bc0c99b8-9387-446b-bc45-09cfb5f9cc33
Vector Index
✗ No vector
Created
September 30, 2026 at 10:01 PM (1 week ago)
Last Updated
September 30, 2026 at 10:01 PM (1 week ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://reason.com/2026/09/30/hazy-federal-criteria-for-classifying-drugs-invite-arbitrary-bureaucratic-judgments
Hazy Drug Classification Criteria Invite Dubious Bureaucratic Judgments
Completed Analysis
10 claims 🔥
1 week ago
https://reason.com/2026/09/30/hazy-federal-criteria-for-classifying-drugs-invite-arbitrary-bureaucratic-judgments

A GAO report notes that the Controlled Substances Act (CSA) does not define "potential for abuse" or "accepted medical use," leading to arbitrary bureaucratic judgments. This lack of clarity has significant criminal justice implications, as seen in the historical treatment of cannabis.

Drug Policy Controlled Substances Act Drug Classification Government Accountability Office DEA FDA Cannabis Reclassification

Similar Claims (5)

Other claims identified as semantically similar to this one.